L. Golding

发表

Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy

K. Jacobson, P. Levett, S. Lawrence, 2021, Gut.

Variability in mRNA SARS-CoV-2 BNT162b2 vaccine immunogenicity is associated with differences in the gut microbiome and habitual dietary fibre intake

B. Vallance, G. Healey, A. Majdoubi, 2022, medRxiv.

Decay of anti-Bordetella pertussis antibodies in women of childbearing age following COVID-19 non-pharmaceutical measures

P. Lavoie, F. Reicherz, L. Golding, 2022, Vaccine.

Waning immunity against respiratory syncytial virus during the COVID-19 pandemic

David J. Marchant, I. Sekirov, P. Lavoie, 2022, The Journal of infectious diseases.

Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals

M. Petric, B. Grunau, P. Levett, 2022, Microbiology spectrum.

Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals.

P. Demers, T. Kirkham, B. Grunau, 2021, JAMA.

Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273

B. Grunau, S. O’Brien, Martin A. Prusinkiewicz, 2022, Microbiology spectrum.

Determining the Optimal SARS-CoV-2 mRNA Vaccine Dosing Interval for Maximum Immunogenicity

B. Grunau, Martin A. Prusinkiewicz, P. Lavoie, 2022, bioRxiv.

Gut microbiome and dietary fibre intake strongly associate with IgG function and maturation following SARS-CoV-2 mRNA vaccination

B. Vallance, G. Healey, P. Lavoie, 2022, Gut.

DDIT4L regulates mitochondrial and innate immune activities in early life

A. Majdoubi, Emma Ackermann, Anne-Sophie Archambault, 2024, JCI insight.